These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35973582)

  • 1. Targeted therapy for breast cancer: An overview of drug classes and outcomes.
    Jacobs AT; Martinez Castaneda-Cruz D; Rose MM; Connelly L
    Biochem Pharmacol; 2022 Oct; 204():115209. PubMed ID: 35973582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy of metastatic breast cancer.
    Sánchez-Muñoz A; Pérez-Ruiz E; Jiménez B; Ribelles N; Márquez A; García-Ríos I; Alba Conejo E
    Clin Transl Oncol; 2009 Oct; 11(10):643-50. PubMed ID: 19828406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards personalized treatment for early stage HER2-positive breast cancer.
    Goutsouliak K; Veeraraghavan J; Sethunath V; De Angelis C; Osborne CK; Rimawi MF; Schiff R
    Nat Rev Clin Oncol; 2020 Apr; 17(4):233-250. PubMed ID: 31836877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer molecular subtypes--modern therapeutic concepts for targeted therapy of a heterogeneous entity.
    Liedtke C; Kiesel L
    Maturitas; 2012 Dec; 73(4):288-94. PubMed ID: 23020990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.
    Kelly CM; Buzdar AU
    Drugs; 2013 May; 73(6):505-15. PubMed ID: 23605692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biology and Management of Patients With Triple-Negative Breast Cancer.
    Sharma P
    Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aiming for the Insulin-like Growth Factor-1 system in breast cancer therapeutics.
    Christopoulos PF; Corthay A; Koutsilieris M
    Cancer Treat Rev; 2018 Feb; 63():79-95. PubMed ID: 29253837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.
    Austreid E; Lonning PE; Eikesdal HP
    Expert Opin Pharmacother; 2014 Apr; 15(5):681-700. PubMed ID: 24579888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research advances and new challenges in overcoming triple-negative breast cancer.
    Zong Y; Pegram M
    Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.
    Santarpia L; Bottai G; Kelly CM; Győrffy B; Székely B; Pusztai L
    Oncologist; 2016 Sep; 21(9):1063-78. PubMed ID: 27384237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
    Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
    Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies.
    Chiec L; Kumthekar P
    CNS Drugs; 2022 Feb; 36(2):167-179. PubMed ID: 35075602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.
    Braccini AL; Azria D; Thezenas S; Romieu G; Ferrero JM; Jacot W
    Breast; 2013 Oct; 22(5):993-8. PubMed ID: 23831232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Novel Therapeutics in Triple-Negative Breast Cancer.
    Lyons TG; Traina TA
    Adv Exp Med Biol; 2019; 1152():377-399. PubMed ID: 31456195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials.
    Huynh MM; Pambid MR; Jayanthan A; Dorr A; Los G; Dunn SE
    Expert Opin Investig Drugs; 2020 Nov; 29(11):1199-1208. PubMed ID: 32869671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment.
    Gu G; Dustin D; Fuqua SA
    Curr Opin Pharmacol; 2016 Dec; 31():97-103. PubMed ID: 27883943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
    Damasceno M
    Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance.
    Curigliano G
    Cancer Treat Rev; 2012 Jun; 38(4):303-10. PubMed ID: 21764517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
    Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
    Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.